课题基金 / 基金详情

Gene Expression and Diagnosis of Autoimmune Disease

Gene Expression and Diagnosis of Autoimmune Disease
自身免疫性疾病的基因表达和诊断
批准号:
6582720
负责人:
Thomas M. Aune
金额:
$13.38万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-02-15 至 2004-06-30

项目摘要

项目成果

Thomas M. Aune的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):自身免疫性疾病,如系统性红斑狼疮、类风湿性关节炎、I型糖尿病和多发性硬化,被认为是由先天或适应性免疫反应异常引起的。自身免疫性疾病通常很难诊断,因为其症状可能是其他疾病的典型症状,而且相当模糊,比如肌肉骨骼的不适和疼痛、头痛或头晕。没有可用的血液测试可以准确地排除具有这些症状的受试者的自身免疫性疾病的可能性。最好的情况是,通常需要一系列的测试和一段时间的观察来确定患者确实患有自身免疫性疾病。因此,一个可以轻易排除自身免疫性疾病可能性的单一测试将使医生能够集中精力在那些最有可能患上严重疾病的患者身上。利用微阵列技术,我们比较了四种不同自身免疫性疾病个体、免疫前后正常对照个体和其他慢性疾病个体外周血单个核细胞基因表达的差异。令人惊讶的是,我们发现每个自身免疫性疾病患者都有一个共同的基因表达特征,它独立于特定的自身免疫性疾病,但与正常的免疫反应完全不同,并且在其他慢性疾病患者中没有观察到。基于这些观察结果,我们开发了一个简单的测试来排除受试者患有自身免疫性疾病的可能性。这种测试的主要优点是它比现有的测试更快、更准确。到目前为止,该测试预测自身免疫性患者和正常患者的准确率为100%。该提案的第一个目标是从足够数量的个体中收集基因表达数据,以设计具有最佳预测能力的测试。第二个目标是通过检查一组尚未明确诊断出自身免疫性疾病的个体来验证该测试。长期目标是利用微阵列实验的结果来开发对自身免疫性疾病患者的治疗管理具有预测价值的测试。这些测试包括对疾病进行分类、预测严重程度和预测最佳治疗方案。
英文摘要
DESCRIPTION (provided by the applicant): Autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, type I diabetes, and multiple sclerosis, are thought to arise from abnormalities of innate or adaptive immune responses. Autoimmune diseases are often difficult to diagnose, as the symptoms can be typical of other conditions and quite vague, such as musculoskeletal complaints and pain, headaches or dizziness. No available blood test can accurately exclude the possibility of an autoimmune disease in a subject with these symptoms. At best, a battery of tests and a period of observation are usually required to establish that a patient does in fact have an autoimmune disorder. Thus, a single test that could readily exclude the possibility of an autoimmune disease would allow physicians to focus their efforts on patients who have the greatest likelihood of serious disease. Using microarray technology, we have compared differences in gene expression in peripheral blood mononuclear cells among individuals with four distinct autoimmune diseases, normal control individuals before and after immunization, and individuals with other chronic diseases. Surprisingly, we find that each individual with autoimmune disease has a common gene expression signature that is independent of the specific autoimmune disease but is totally distinct from the normal immune response and is not observed in individuals with other chronic diseases. Based upon these observations, we have developed a simple test for excluding the possibility that a subject has an autoimmune disorder. The main advantage of this test is that it is a quicker and more accurate test than those currently available. This test has thus far predicted autoimmune patients from normal patients with 100 percent accuracy. The first goal of this proposal is to collect gene expression data from a sufficient number of individuals to design a test with optimal predictive power. The second goal is to validate the test by examining a cohort of individuals who do not yet carry a clear-cut diagnosis of an autoimmune disease. Long-term goals are to use results from microarray experiments to develop tests that have predictive value for the therapeutic management of individuals with autoimmune diseases. These include tests that classify diseases, predict severity, and predict the best therapeutic options.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1038/gene.2011.66
发表时间: 2012-02
期刊: GENES AND IMMUNITY
影响因子: 5
作者: [Tossberg, J. T., Crooke, P. S., Henderson, M. A., Sriram, S., Mrelashvili, D., Chitnis, S., Polman, C., Vosslamber, S., Verweij, C. L., Olsen, N. J., Aune, T. M.]
通讯作者: Aune, T. M.
DOI: 10.1186/2043-9113-3-18
发表时间: 2013-10-03
期刊: Journal of clinical bioinformatics
影响因子: --
作者: [Tossberg JT, Crooke PS, Henderson MA, Sriram S, Mrelashvili D, Vosslamber S, Verweij CL, Olsen NJ, Aune TM]
通讯作者: Aune TM
Alu dsRNAs as adjuvants for influenza vaccines
Alu dsRNAs as adjuvants for influenza vaccines
Loss of A-to-I editing stimulates SARS-CoV-2 anti-viral responses
Loss of A-to-I editing stimulates SARS-CoV-2 anti-viral responses
海外基金